

THE RENAISSANCE ERA OF LUNG CANCER THERAPIES

LUNG CANCER EUROPEAN MEETING (LuCE-M)

CME ID 2157-229486

The International Congress "LUCM THE RENAISSANCE ERA OF LUNG CANCER THERAPIES Lung Cancer European Meeting-(LUCM 2)" is credited for up to 100 participants and has been awarded for the following professions: **medical surgeon (all disciplines), healthcare assistant, biologist and nurse**. The credits (**8 assigned**) will be provided with a complete participation in scientific work and learning exam with at least 75% of correct answers.

Inscription

Membership is free and entitles you to participation in Congress, Conference kit, certificate of attendance, coffee-break and lunch buffet. To enroll, send your personal data (name, surname, telephone number, e-mail), to the following address email: info@medicacom.it, or at the following fax number: **02 93661995**. For organizational purposes, entries must be received by July 4th, 2018.

CHAIRMAN

Diego Luigi Cortinovis: Medical Oncology Unit, ASST Ospedale San Gerardo, Monza, Italy

FACULTY

Francesco Agostoni: Medical Oncology, ASST Ospedale San Gerardo, Monza, Italy

Paolo Bidoli: S.C. Medical Oncology Unit, ASST Ospedale San Gerardo, Monza, Italy

Ramesh Bulusu: Consultant Oncologist and UK Lead Clinician for PAWS GIST Clinic

Raffaele Califano: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom

Stefania Canova: Medical Oncology, ASST Ospedale San Gerardo, Monza, Italy

Francesca Colonese: Medical Oncology, ASST Ospedale San Gerardo, Monza, Italy

Jesus Corral: Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain

Levra Matteo Giaj: Medical Oncology Unit and Thoracic Oncology, Centre hospitalo-universitaire de Grenoble - Hôpital Michallon, France

Bazo Ignacio Gil: Medical Oncology Department, Clínica Universidad de Navarra - Center for Applied Medical Research, Pamplona, Spain

Niki Karachaliou: University Hospital Sagrat Cor Instituto Oncológico Rosell (IOR), Barcelona, Spain

Zoltan Lohinai: Medical Pulmonary Oncology, Koranyi Institute of Pulmonology, Budapest, Hungary

Marcus Pantarotto: Medical Oncology, Hospital Da Luz, Lisbona, Spain

Niels Reinmuth: Oncology Director, Thoracic Oncology Department at the Asklepios Lung Clinic in Munich-Gauting, Germany

Marco Scarci: Primary director of thoracic surgery, Ospedale San Gerardo ASST Monza

Justin Stebbing: Professor of Cancer Medicine and Oncology Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust, London, United Kingdom

Marcello Tiseo: Medical Oncology, A.O.U., Parma, Italy

Anne Claire Toffart: Associate Professor, Clinique de Pneumologie, Pôle Thorax et Vaisseaux, CHU Grenoble Alpes, France

Luca Toschi: Oncology and Hematology Department, Istituto Clinico Humanitas, IRCCS Rozzano, Milano, Italy

PATRONAGE ON REQUEST:



Secondo le finalità
della Rete
Oncologica Regionale



With the unrestricted grant of:



With the presence of:



THE RENAISSANCE ERA OF LUNG CANCER THERAPIES

LUNG CANCER EUROPEAN MEETING (LuCE-M)

Friday, July 6th, 2018

Congress Center Ospedale San Gerardo, Monza

Chairman

Diego Cortinovis

Provider CME, Scientific and Organizational Secretariat

Medica
EDITORIA E
DIFFUSIONE
SCIENTIFICA

Medica Editoria e Diffusione Scientifica
Corso Buenos Aires, 43 - 20124 Milano
Tel +39 02 7628 1337 - Fax +39 02 9366 1995
info@medicacom.it

Medica
EDITORIA E
DIFFUSIONE
SCIENTIFICA

Provider CME, Scientific and Organizational Secretariat

THE RENAISSANCE ERA OF LUNG CANCER THERAPIES

LUNG CANCER EUROPEAN MEETING (LuCE-M)

SCIENTIFIC RATIONALE

The therapeutic pathways in managing non-small cell lung cancer are now extremely complex and articulated and start from a basic biomolecular evaluation. This evaluation aims to provide the clinician with the tools needed for precision medicine.

Immunotherapy are nowadays a cornerstone in therapeutic strategy from first line setting making 20% of lung cancer a true chronic disease, however little is known in clinical practice about overcoming the resistance to antiPD1 and antiPDL1 agents.

Antiangiogenic therapies become valuable-allies in the fight against this type of cancer. The availability and applicability in clinical practice can create long-term survivors following this diagnosis.

A better knowledge about the clonal evolution of cancer together the understanding of links with microenvironment makes lung cancer a model to discover new ways to harness its devastating behaviour.

These aspects are further corroborated by the clinical research and networks.

The international collaboration between clinicians and investment in biomolecular platforms are the key to truly effective and powerful research needed to ensure optimal targeted therapy for each tumor.

AGENDA

THE RENAISSANCE ERA OF LUNG CANCER THERAPIES

D. Cortinovia (Chairman)

10.00 Welcome and introduction:
D. Cortinovia, P. Bidoli, M. Scarci (Moderator)

FIRST SESSION: THE MIDDLE AGE

D. Cortinovia, L. Toschi (Moderator)

10.15 The role of chemotherapy in 2018:
is there already a place?
J. Corral

10.35 Discussion corner
All

10.50 Pharmacogenomics and epigenetics:
new discoveries of old fashion Cts
N. Reinmuth

11.10 Discussion corner
All

11.25 Antiangiogenic agents:
Folkman's promise or Morgana effect
A. C. Toffart

11.45 Discussion corner
All

12.00 Lecture: Lung cancer clonal heterogeneity
and application in early disease detection
J. Stebbing

12.30 LUNCH

SECOND SESSION: THE RENAISSANCE

P. Bidoli (Moderator)

13.00 Immune breaking news in first and further lines
R. Bulusu

13.20 Discussion corner
All

13.35 Micro-environment manipulation:
predictive factors of ICI activity
R. Califano

13.55 Discussion corner
All

14.10 EGFR TKI: the winner is....
N. Karachaliou

14.40 Discussion corner
All

14.55 ALK TKI: the winner is....
M. Pantarotto

15.25 Discussion corner
All

15.40 An interactive clinical case
F. Colonese, F. Agustoni

THIRD SESSION: POST-ATOMIC AGE

S. Canova, M. Tiseo (Moderator)

16.10 Immune combos: IO+IO or CT+IO?
Z. Lohinai

16.30 Discussion corner
All

16.45 Targeted agents over the resistance mechanisms
I. Gill Bazo

17.10 Discussion corner
All

17.25 The sustainability of new drugs
M. Gaj Levra

17.45 Final Discussion:
Open my mind: drawing new therapeutic algorithm
All

18.30 Closing Remarks and final test CME